Login / Signup

Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by Sparks et al.

Zachary S WallaceJeffrey A SparksPhilip C RobinsonPedro M MachadoJinoos Yazdany
Published in: Annals of the rheumatic diseases (2021)
Keyphrases
  • rheumatoid arthritis
  • coronavirus disease
  • sars cov
  • disease activity
  • rheumatoid arthritis patients
  • cancer therapy
  • ankylosing spondylitis
  • interstitial lung disease
  • respiratory syndrome coronavirus